Biotechnology

The opportunity: a more efficient bioreactor could increase your operation’s profitability From vaccine production in the biotech industry to alternative proteins, manufacturers face pressure to increase their bottom line by building more efficiency into their operations. What sets them apart, though, is a unique ace up their sleeve: bioreactors.

Use the automation pyramid as a roadmap to navigate the transition from lab-scale ATMP manufacturing to a cGMP facility that’s compliant, optimized, and future-ready.

To move advanced therapy medicinal products (ATMPs) from the lab to the commercial-scale manufacturing facility, you need a future-proof plan. These 6 questions will help you create one.

For viral vectors to mature into a commercially successful submarket that’s accessible to patients, manufacturers need novel solutions and facilities designed for flexibility, scalability, and long-term innovation.

Real talk from the front lines of today’s research and manufacturing landscape

Decades of scientific progress in understanding the root cause of many formerly intractable diseases has opened up new treatment options, namely through RNA-based therapies. This second wave of biopharma, in which our understanding of the ways coding portions of our genome relate to disease, allows us to intercede earlier, and at more specific and effective junctures.

What are the environmental impacts of single-use technology and stainless steel systems? And which should you use in your next facility?